- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07803029
Bioimpedance Spectroscopy (BIS): Fluid Changes in Hemodialysis Patients
Bioimpedance Spectroscopy (BIS): Analysis of Changes in Fluid Status in Hemodialysis Patients
Study Overview
Detailed Description
To investigate whether raw impedance data from BIS measurements can be used as a tool to estimate changes in fluid status in HD patients. Accuracy is low when using prediction equations that are integrated into the individual BIS device. This challenges the application in clinical practice. Furthermore, the prediction equation is not available for most devices. Small studies suggest greater accuracy when using raw data, which could make BIS measurements clinically applicable. Detailed purpose. To examine whether raw impedance data from BIS measurements can be used as a tool to estimate changes in fluid status in HD patients.
- Ensure consistency in measurements of raw impedance data (Phase angle, RE, RI, R∞, and Cm) between different BIS devices (here: Fresenius BCM®, SFB7®, and SOZO® from ImpediMed).
- Compare intradialytic ∆RE, ∆R∞, and ∆Cm against changes in absolute blood volume, BP, weight, and fluid removal in HD patients with fluid removal.
- Is the phase angle consistent over the 3 dialysis days in a week for center dialysis patients with fluid retention?
- Compare intradialytic ∆RE, ∆R∞, and ∆Cm against changes in absolute blood volume, blood pressure, and weight in hemodialysis patients without fluid retention.
- Compare intradialytic ∆blood pressure, ∆weight, ∆ABV, fluid retention, and BIS measured changes (∆RE, ∆R∞, ∆Cm) for patients undergoing home hemodialysis with patients undergoing center hemodialysis.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Per Ivarsen, MD
- Phone Number: +457845000
- Email: per.ivarsen@clin.au.dk
Study Locations
-
-
Central Denmark
-
Aarhus, Central Denmark, Denmark, 8200
- Recruiting
- Aarhus University Hospital
-
Contact:
- Per Ivarsen, MD
- Phone Number: +457845000
- Email: per.ivarsen@clin.au.dk
-
Contact:
- Email: per.ivarsen@clin.au.dk
-
Principal Investigator:
- Per Ivarsen, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Hemodialysis for more than 3 month Hemodynamic stabile during a dialysis session
-
Exclusion Criteria:
- Amputated limbs.
- Pregnant.
- Extremity palsy and paralysis.
- Implanted electronic device (e.g., pacemaker or ICD).
- Regular use of dialysate sodium proliferation.
- Hip, knee and shoulder prosthesis.
- Dialysis fistula in both arms.
- Inability to give informed consent.
- History of discontinuation of dialysis treatment prematurely.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Hemodialysis patient
Measurement wil be donne before and after a hemodialysis.
Bioimpendance spectroscopy is measured with 3 different bioimpedance apperatur.
Absolute blood volumen is measured 5-10 minutes after starting and before stopping the dialysis session.
For center hemodialysis patients with ultrafiltration measurement til be performed on 3 consecutive days and for patient center hemodialysis patient meaurement wil be performed once with also apply for Home hemodialysis patients.
|
Comparing the perfomance of original data from 3 different bioimpedance apparatur and test there precision and accurary compared to ultrafiltration.
And whether the performance of measuring absolut blood volume is better
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in BIS measured resistance and fluid removed
Time Frame: From enrollment to the end of the dialysis session
|
To investigate whether raw impedance data from BIS measurements can be used as a tool to estimate changes in fluid status in HD patients before and after a hemodialysis session of 4 hours duration. Weight loss during a hemodialysis session is equivalent to fluid removed. The meausement are don for up to oen week
4) In a subset of patients test if the length of the of pause (days) between hemodialysis session influence the raw impedance measurements. |
From enrollment to the end of the dialysis session
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VMK2500694
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.